Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial.

被引：0
|
作者：
Bharucha, Kamal N. [1 ]
Brunner, Hermine I. [2 ]
Ruperto, Nicola [3 ]
Cabral, David A. [2 ]
Gedalia, Abraham [2 ]
Gerloni, Valeria [3 ]
Jorgensen, Christian [3 ]
Ramanan, Athimalaipet [3 ]
Lovell, Daniel [2 ]
Martini, Alberto [4 ]
Frane, James
Wells, Chris [5 ]
De Benedetti, Fabrizio, Sr. [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] PRCSG, Cincinnati, OH USA
[3] PRINTO, Genoa, Italy
[4] Ist Giannina Gaslini, I-16148 Genoa, Italy
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[6] Osped Pediat Bambino Gesu, IRCCS, Div Rheumatol, Rome, Italy
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
276
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [41] Tocilizumab improves systemic and laboratory features of Systemic Juvenile Idiopathic Arthritis: 12-week data from the Phase 3 TENDER Trial
    De Benedetti, F.
    Rome, Bambin Gesu
    Ruperto, N.
    Brunner, H.
    Baildam, E.
    Burgos, R.
    Dolezalova, P.
    Garay, S.
    Garcia-Consuegra, J.
    Joos, R.
    Wulffraat, N.
    Zuber, Z.
    Zulian, F.
    Grom, A.
    Schaefer, F.
    Wright, S.
    Kenwright, A.
    Martini, A.
    Lovell, D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 415 - 415
  • [42] Efficacy and safety of tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week data from the Phase 3 TENDER trial
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Calvo, I.
    Cutica, R.
    Malattia, C.
    Schneider, R.
    Woo, P.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Wright, S.
    Kenwright, A.
    Lovell, D.
    Martini, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 371 - 371
  • [43] Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study
    Ruperto, Nicolino
    Lovell, Daniel J.
    Berman, Alberto
    Avila-Zapata, Francisco
    Horneff, Gerd
    Alessio, Maria
    Becker, Mara L.
    Belot, Alexandre
    Burgos-Vargas, Ruben
    Gamir, Maria L.
    Goldenstein-Schainberg, Claudia
    Scheibel, Iloite M.
    Terreri, Maria T.
    Zemel, Lawrence
    Zhuo, Joe
    Askelson, Margarita
    Wong, Robert
    Martini, Alberto
    Brunner, Hermine I.
    [J]. ARTHRITIS CARE & RESEARCH, 2023, : 1804 - 1814
  • [44] Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial.
    Burmester, Gerd
    Rigby, William
    van Vollenhoven, Ronald F.
    Kay, Jonathan
    Rubbert-Roth, Andrea
    Blanco, Ricardo
    Kelman, Ariella
    Dimonaco, Sophie
    Mitchell, Nina
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S811 - S812
  • [45] Tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetic (PK) and Pharmacodynamic (PD) data from the Phase 3 TENDER Trial
    Ruperto, N.
    Zhang, A.
    Morcos, P. N.
    Huppertz, H.
    Minden, K.
    Myones, B.
    Onel, K.
    Siammopoulou, A.
    Silva, C.
    Kenwright, A.
    Roseti, S.
    De Benedetti, F.
    Lovell, D.
    Martini, A.
    Brunner, H.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 421 - 421
  • [46] Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis - an Extension Study of 2 Phase 1b Clinical Trials
    Brunner, Hermine
    Ramanan, Athimalaipet
    Horneff, Gerd
    Minden, Kirsten
    Calvo Penades, Inmaculada
    Zucchetto, Mauro
    Brockwell, Laura
    Gordon, Oliver
    De Benedetti, Fabrizio
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4390 - 4393
  • [47] PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
    C Malattia
    N Ruperto
    E Palmisani
    S Pederzoli
    A Pistorio
    HI Brunner
    R Cuttica
    I Calvo
    SM Garay
    D Eleftheriou
    C Wouters
    J Wang
    C Devlin
    D Lovell
    A Martini
    F De Benedetti
    A Ravelli
    [J]. Pediatric Rheumatology, 11 (Suppl 2)
  • [48] Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study
    Heiligenhaus, Arnd
    Klotsche, Jens
    Tappeiner, Christoph
    Sengler, Claudia
    Niewerth, Martina
    Liedmann, Ina
    Hoeft, Sabine
    Walscheid, Karoline
    Lavric, Miha
    Foell, Dirk
    Minden, Kirsten
    [J]. RHEUMATOLOGY, 2019, 58 (06) : 975 - 986
  • [49] Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial.
    Khanna, Dinesh
    Denton, Christopher P.
    van Laar, Jacob M.
    Jahreis, Angelika
    Cheng, Sabrina
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S386 - S386
  • [50] Improvement in Patient-Reported Outcomes in Patients Aged 2-5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
    Brunner, Hermine
    Tzaribachev, Nikolay
    Louw, Ingrid
    Anton, Jordi
    Viola, Diego
    Lauwerys, Bernard
    Cuttica, Ruben J.
    Quartier, Pierre
    Gervais, Elisabeth
    Belot, Alexandre
    Minden, Kirsten
    Lutz, Thomas
    Cimaz, Rolando
    Ally, Mahmood M. T. M.
    van Zyl, Riana
    Penades, Inmaculada Calvo
    Zhuo, Joe
    Wong, Robert
    Nys, Marleen
    Elbez, Yedid
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345